Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.
Member count: 11-50
Total raised: $7.8M
Founded date: 2010
Investors 2
| Date | Name | Website |
| - | New Scienc... | newscience... |
| - | Easton Cap... | eastoncapi... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 01.11.2012 | Series B | $5.8M | - | geekwire.c... |
| 17.05.2011 | Series A | $2M | - | finsmes.co... |
Mentions in press and media 6
| Date | Title | Description | Category | Author | Source |
| 01.11.2012 | Resolve Th... | SEATTLE, WA, Company has rai... | - | - | vcnewsdail... |
| 01.11.2012 | Resolve Th... | Resolve Therapeutics, a 2-year... | - | John Cook | geekwire.c... |
| 01.11.2012 | New anti-i... | With the new money, Resolve wi... | - | - | medcitynew... |
| 01.11.2012 | Resolve Th... | Resolve Therapeutics, a Seattl... | funding U... | - | finsmes.co... |
| 17.05.2011 | Resolve Th... | Resolve Therapeutics, LLC, a S... | funding U... | - | finsmes.co... |
| - | New anti-i... | The approval of Human Genome S... | - | - | medcitynew... |